China Bribery Scandal Could Provide Fodder For U.S. Foreign Corrupt Practices Act Investigations
This article was originally published in The Pink Sheet Daily
Companies under scrutiny in China for allegedly bribing doctors could face new enforcement actions in the U.S. Lilly’s ability to avoid another FCPA investigation may depend on whether the SEC was aware of whistleblower allegations made in the Chinese press.
You may also be interested in...
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.
The agency's "Bad Ad" program issued a warning letter that claims the promotion for CooperSurgical's copper-containing intrauterine contraceptive lacked any safety information.
During oral argument in the Arthrex case, several justices seemed to agree with the Federal Circuit that PTAB judges should have been appointed by the president. They could opt to get around the problem by enabling the PTO director to review all panel decisions.